Replies to post #146651 on Biotech Values

[DewDiligence]

Also AMGN-ABGX. I'll update the list.

[DewDiligence]

Biotech-Partnership Buyouts (updated)

Many drug/biotech partnerships eventually result in buyout offers.
Here are a few examples in descending order of buyout premium
(thanks to jq1234 for contributing additional cases):

 
 Roche-MEMY  319% 
 PFE  -COLY  167% 
 PFE  -ICGN  150% 
 LLY  -SGXP  119% 
 PFE  -ENCY  118% 
 GSK  -HGSI   99% 
 NVS  -Spdel  94% 
 BMY  -MEDX   90% 
 BMY  -ZGEN   84% 
 BIIB -FACT   64% (outbid by ABT) 
 JNJ  -CRXL   58% 
 LLY  -ICOS   54% 
 AMGN -ABGX   54% 
 BMY  -IMCL   51% (outbid by LLY) 
 MRK  -SGP    34% 
 AMGN -MITI   33%